Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective.

Autor: Dhanji N; Modeling & Meta-Analysis, OPEN Health, Oxford, UK., Decimoni TC; Health Economics and Outcomes Research, Bristol Myers Squibb, São Paulo, SP, Brazil., Dyer MTD; WW Health Economics and Outcomes Research, Bristol Myers Squibb, Uxbridge, UK., May JR; WW Health Economics and Outcomes Research, Bristol Myers Squibb, Uxbridge, UK., van de Wetering G; Modeling & Meta-Analysis, OPEN Health, Rotterdam, Netherlands., Petersohn S; Modeling & Meta-Analysis, OPEN Health, Rotterdam, Netherlands., Nickel K; Modeling & Meta-Analysis, OPEN Health, Berlin, Germany., Silva A; Commercialization Intercon Medical, Medical and Regulatory Affairs, São Paulo, SP, Brazil., Muniz DQB; Hospital Sírio-Libanês, São Paulo, Brazil., Casagrande D Oliveira AP; Health Economics and Outcomes Research, Bristol Myers Squibb, São Paulo, SP, Brazil.

Publikováno v: Journal of medical economics [J Med Econ] 2023 Jan-Dec; Vol. 26 (1), pp. 1108-1121.